Lidocain Aguettant (Lidocaine Hydrochloride)

Lidocaine blocks voltage‑gated sodium channels on nerve membranes, preventing the rapid influx of sodium ions needed for depolarisation. By inhibiting nerve impulse generation and propagation, it produces a reversible loss of sensation in the area where it is administered, while typically preserving motor function.

The appropriate dose of Lidocain Aguettant is determined by the prescribing clinician based on the specific procedure, patient characteristics, and route of administration. Healthcare professionals calculate the dose to achieve effective anesthesia while minimising the risk of systemic toxicity.

Safety data for lidocaine in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any potential risk to the fetus or infant. Clinicians should assess each case individually and consider alternative options when possible.

To request Lidocain Aguettant, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Lidocaine is an amide‑type local anesthetic with a rapid onset and moderate duration, making it suitable for many short‑to‑medium procedures. Compared with ester‑type agents such as procaine, lidocaine has a lower incidence of allergic reactions and a more predictable pharmacokinetic profile, though alternatives like bupivacaine may offer longer lasting anesthesia.

Lidocain Aguettant should be stored at temperatures below 25 °C, protected from moisture, light and extreme heat. Keep the vial in its original packaging until use, and avoid freezing. Follow standard aseptic techniques when preparing for injection.

The product is supplied as an injectable solution. It can be administered by infiltration into the target tissue, intradermally for superficial anesthesia, or intravenously under controlled conditions for antiarrhythmic therapy. Administration technique and volume are determined by the treating clinician.

Serious adverse events include central nervous system toxicity such as seizures, severe cardiac effects like arrhythmias or cardiac arrest, and rare allergic reactions including anaphylaxis. Prompt recognition and supportive management are essential if these events occur.

Patients with a known hypersensitivity to lidocaine or other amide‑type local anesthetics, those with severe hepatic impairment, and individuals with certain cardiac conduction disorders should avoid using Lidocain Aguettant unless a specialist determines that benefits outweigh risks.